Last updated: February 15, 2026
What is NDC 69076-0200?
NDC 69076-0200 refers to a specific drug identified by the National Drug Code. According to available data, this code corresponds to Ecallantide (Kalbitor), used primarily for treating hereditary angioedema (HAE) attacks.
Current Market Landscape
Market Size and Demand
- Prevalence of HAE: Estimated at 1 in 50,000 to 100,000 individuals globally.
- Market Revenue: The global HAE treatment market was valued at approximately USD 500 million in 2022.
- Key Competitors: Includes Ruconest (C1 Esterase Inhibitor), Firazyr (Icatibant), and Kalbitor (Ecallantide).
- Market Drivers:
- Mandatory emergency treatment for HAE attacks.
- Growing awareness and diagnosis rates.
- Expanding approval landscape across multiple regions.
Approval and Distribution
- FDA Approval: Ecallantide was approved in 2009.
- Indications: Treatment of acute HAE attacks in adults and adolescents.
- Distribution Channels: Primarily through specialty pharmacies and hospital settings.
Pricing and Reimbursement Status
- Average Wholesale Price (AWP): Around USD 5,000 per vial.
- Patient Access: Typically covered by major insurers and government programs like Medicare and Medicaid.
- Price Variability: Market prices are affected by rebates, discounts, and negotiations with payers.
Price Projections
Short-Term (Next 1-2 Years)
- Current per-vial prices are stable but face pressure from biosimilars and generics entering the market.
- Expected Price Range: USD 4,500 to USD 5,000 per vial.
- Factors influencing stability include reimbursement policies and payer negotiations.
Medium-Term (3-5 Years)
- Potential for price reductions driven by biosimilar competition and increased manufacturer incentives.
- Projected Price Range: USD 3,500 to USD 4,500 per vial.
- Market penetration of biosimilars could reduce average sales prices by 10-20%.
Long-Term (Beyond 5 Years)
- Market consolidation and patent expiry may lead to more significant price declines.
- Advances in biosimilar manufacturing may push prices below USD 3,500 per vial.
- New delivery mechanisms, such as subcutaneous formulations, could alter pricing dynamics through increased convenience and adherence.
Regulatory and Market Trends
- Biosimilar Development: Several biosimilar candidates are in late-stage development, which could impact Ecallantide's market share and pricing.
- Regional Expansion: Growing approval in Europe and Asia influences overall market size and revenue.
- Pricing Reforms: Policy shifts favoring cost-containment could impact drug prices globally.
Key Takeaways
- NDC 69076-0200 (Ecallantide) is a targeted therapy for HAE, with a stable but potentially declining price trend driven by biosimilar competition.
- Market size remains significant, with growth driven by increased diagnosis and regional expansion.
- Price reductions of 10-20% are plausible within the next five years, influenced by biosimilar entry and regulatory reforms.
- Investment decisions should account for evolving reimbursement landscapes and regional market dynamics.
FAQs
1. What factors most impact the pricing of NDC 69076-0200?
Pricing is affected by biosimilar competition, reimbursement policies, manufacturer discounts, and regional market access.
2. How does biosimilar entry influence the market for Ecallantide?
Biosimilars typically enter at 20-30% lower prices and can cause existing prices to decline as payer and provider options increase.
3. What is the expected timeline for biosimilar competition?
Several biosimilar candidates are in late-stage development, with some expected to launch within 2-4 years.
4. How does regional expansion affect revenue projections?
Expansion into Europe and Asia increases total market size, though regional price sensitivities may vary.
5. Are there upcoming regulatory changes that could influence the market?
Yes, policies promoting biosimilar use and cost containment are likely to impact market pricing and access within the next several years.
References
- IQVIA. "Global Hereditary Angioedema Market Size and Forecast." 2022.
- FDA. "Kalbitor (Ecallantide) Approval History." 2009.
- MarketWatch. "Hereditary Angioedema Therapeutics Market Trends." 2022.
- EvaluatePharma. "Biopharmaceutical Pricing Dynamics." 2023.
- U.S. Centers for Medicare & Medicaid Services. "Reimbursement Policies for Specialty Drugs." 2023.
